

Aug 01, 2020

© Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization

Bei Wang¹, Daniel Asarnow^{2,3}, Wen-Hsin Lee¹, Ching-Wen Huang¹, Bryan Faust^{2,3}, Patricia Miang Lon Ng¹, Eve Zi Xian Ngoh¹, Markus Bohn^{3,4}, David Bulkley^{2,3}, Andrés Pizzorno⁵, Hwee Ching Tan¹, Chia-Yin Lee¹, Rabiatul Adawiyah Minhat¹, Olivier Terrier⁵, Mun Kuen Soh¹, Frannie Jiuyi Teo¹, Yvonne Yee Chin Yeap¹, Yuanyu Hu¹, Shirley Gek Kheng Seah⁶, Sebastian Maurer-Stroh⁷, Laurent Renia^{1,8,9}, Brendon John Hanson⁶, Manuel Rosa-Calatrava^{5,10}, Aashish Manglik^{3,4,11}, Yifan Cheng^{2,3,12}, Charles S. Craik^{3,4}, Cheng-I Wang¹

¹²Howard Hughes Medical Institute, University of California San Francisco (UCSF), San Francisco, USA



ABSTRACT

In vitro antibody selection against pathogens from naïve combinatorial libraries can yield various classes of antigen-specific binders that are distinct from those evolved from natural infection. Also, rapid neutralizing antibody discovery can be made possible by a strategy that selects for those interfering with pathogen and host interaction. Here we report the discovery of antibodies that neutralize SARS-CoV-2, the virus responsible for the COVID-19 pandemic, from a highly diverse naïve human Fab library. Lead antibody 5A6 blocks the receptor binding domain (RBD) of the viral spike from binding to the host receptor angiotensin converting enzyme 2 (ACE2), neutralizes SARS-CoV-2 infection of Vero E6 cells, and reduces viral replication in reconstituted human nasal and bronchial epithelium models. 5A6 has a high occupancy on the viral surface and exerts its neutralization activity via a bivalent binding mode to the tip of two neighbouring RBDs at the ACE2 interaction interface, one in the "up" and the other in the "down" position, explaining its superior neutralization capacity. Furthermore, 5A6 is insensitive to several spike mutations identified in clinical isolates, including the D614G mutant that has become dominant worldwide. Our results suggest that 5A6 could be an effective prophylactic and therapeutic treatment of COVID-19.

EXTERNAL LINK

https://www.biorxiv.org/content/10.1101/2020.07.14.203414v1?rss=1

DOI

dx.doi.org/10.17504/protocols.io.bi35kgq6

COLLECTION CITATION

Bei Wang, Daniel Asarnow, Wen-Hsin Lee, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus Bohn, David Bulkley, Andrés Pizzorno, Hwee Ching Tan, Chia-Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek

protocols.io

08/01/2020

Citation: Bei Wang, Daniel Asarnow, Wen-Hsin Lee, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus Bohn, David Bulkley, Andrés Pizzorno, Hwee Ching Tan, Chia-Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek Kheng Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang (08/01/2020). Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization. https://dx.doi.org/10.17504/protocols.jo.bi35kgg6

¹Singapore Immunology Network, A*STAR, Singapore;

²Department of Biochemistry and Biophysics, University of California San Francisco (UCSF) School of Medicine, San Francisco, US A;

³QBI COVID-19 Research Group (QCRG), San Francisco, USA;

⁴Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, USA;

⁵Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Lyon, France;

⁶Biological Defence Program, DSO National Laboratories, Singapore; ⁷Bioinformatics Institute, A*STAR, Singapore;

⁸School of Biological Sciences, Nanyang Technological University, Singapore;

⁹Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;

¹⁰VirNext, Faculté de Médecine RTH Laennec, Université de Lyon, Lyon, France;

¹¹Department of Anesthesia and Perioperative Care, University of California San Francisco (UCSF), San Francisco, USA;

Kheng Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang 2020. Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization. **protocols.io** dx.doi.org/10.17504/protocols.io.bi35kgq6

EXTERNAL LINK https://www.biorxiv.org/content/10.1101/2020.07.14.203414v1?rss=1 SARS-CoV-2, COVID-19, SARS-CoV, coronavirus, spike protein, monoclonal antibody, phage display LICENSE This is an open access collection distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited CREATED Jul 28, 2020 LAST MODIFIED Aug 01, 2020 COLLECTION INTEGER ID 39773 **FILES** anti-SARS-CoV-2 spike RBD antibody discovery from phage display library by Bei Wang IgG expression and purification Antibody characterizations by BioLayer Interferometry (BLI) by Bei Wang

protocols.io 2 08/01/2020

Antibody neutralization assay with SARS-CoV-2 and SARS-CoV pseudovirus

by Bei Wang